PURCHASE, NY, January 31, 2007 -- Nutrition 21, Inc. (NASDAQ: NXXI) reported today that a peer reviewed analysis on chromium picolinate was published in the current edition of Diabetes Technology & Therapeutics. The analysis confirms that chromium picolinate is effective in improving glycemic control and normalizing lipid levels in people with type 2 diabetes.(1) The review, which analyzed research on chromium picolinate, supports the consistent beneficial effects of chromium picolinate and refutes a previous review that analyzed efficacy after combining results from all types of supplemental chromium.(2)
"The main messages are that all forms of chromium are not equivalent, and that higher doses of chromium picolinate are required for people with type 2 diabetes," said C. Leigh Broadhurst, PhD, Research Chemist, the lead author of the publication. "Previous chromium reviews examined all types of chromium at widely varying doses. But separating out chromium picolinate, which yields highly consistent results in research studies, compared to other chromium supplements shows that at doses between 200--1000 mcg it is a superior nutritional adjunct to diabetes treatments."
The review analyzed 15 clinical studies of people with diabetes. All studies showed chromium picolinate produced benefits in one or more standard measures of diabetes management, with no adverse events reported. The studies examined people with type 2, type 1, gestational and corticosteroid-induced diabetes. Although glycemic control varied by trial, all 15 trials showed improvements in one or more measurements of glycemic control, including fasting glucose, postprandial glucose, fasting insulin, postprandial insulin, glycated hemoglobin, or insulin sensitivity. The authors concluded the greater bioavailability of chromium picolinate compared to other forms of chromium may explain its comparatively significant superior effects on glycemic and lipidemic control.